Masahide Mori

Osaka, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 119 publications

Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancer.

Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 08, 2026

Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer.

Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: February 26, 2026

Impact of pre-existing interstitial lung abnormalities on pneumonitis risk and survival in chemo-naive patients with non-small-cell lung cancer receiving pembrolizumab plus chemotherapy.

Impact of pre-existing interstitial lung abnormalities on pneumonitis risk and survival in chemo-naive patients with non-small-cell lung cancer receiving pembrolizumab plus chemotherapy.

Journal: Respiratory medicine

Published: December 24, 2025

A phase II study of DFP-14323, a non-specific immunomodulator, in combination with low-dose afatinib as first-line therapy for common EGFR mutation-positive NSCLC.

A phase II study of DFP-14323, a non-specific immunomodulator, in combination with low-dose afatinib as first-line therapy for common EGFR mutation-positive NSCLC.

Journal: Therapeutic advances in medical oncology

Published: November 24, 2025

Impact of Sequential Ramucirumab Plus Docetaxel After PD-1 Inhibitors on Anti-PD-1 Antibody-Bound T-Cell Dynamics and Clinical Outcomes.

Impact of Sequential Ramucirumab Plus Docetaxel After PD-1 Inhibitors on Anti-PD-1 Antibody-Bound T-Cell Dynamics and Clinical Outcomes.

Journal: Cancer science

Published: November 17, 2025

Corrigendum to "Timing of first pembrolizumab infusion and long-term outcomes in non-small cell lung cancer: A retrospective multicenter study" [Eur J Cancer. 2025;228:115748].

Corrigendum to "Timing of first pembrolizumab infusion and long-term outcomes in non-small cell lung cancer: A retrospective multicenter study" [Eur J Cancer. 2025;228:115748].

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 04, 2025

Multicenter retrospective study of selpercatinib treatment for advanced or recurrent RET fusion-positive non-small cell lung cancer in Japan.

Multicenter retrospective study of selpercatinib treatment for advanced or recurrent RET fusion-positive non-small cell lung cancer in Japan.

Journal: Investigational new drugs

Published: August 30, 2025

Single-cell spatial analysis identifies ID1-high endothelial cells in tertiary lymphoid structures as predictors of durable response to immunotherapy in non-small cell lung cancer.

Single-cell spatial analysis identifies ID1-high endothelial cells in tertiary lymphoid structures as predictors of durable response to immunotherapy in non-small cell lung cancer.

Journal: Cancer cell international

Published: August 21, 2025

Efficacy of pembrolizumab plus pemetrexed in older patients with non-squamous NSCLC according to PD-L1 expression status: Results from the CJLSG1901 study.

Efficacy of pembrolizumab plus pemetrexed in older patients with non-squamous NSCLC according to PD-L1 expression status: Results from the CJLSG1901 study.

Journal: Cancer treatment and research communications

Published: August 21, 2025

Clinical Outcomes of First-Line Pembrolizumab Monotherapy in Advanced NSCLC With PD-L1 Tumor Proportion Score of 1% to 49%: A Retrospective Multicenter Study.

Clinical Outcomes of First-Line Pembrolizumab Monotherapy in Advanced NSCLC With PD-L1 Tumor Proportion Score of 1% to 49%: A Retrospective Multicenter Study.

Journal: JTO clinical and research reports

Published: August 18, 2025

Long-term survival comparison of first-line pembrolizumab versus pembrolizumab plus chemotherapy for patients with advanced non-small cell lung cancer: A multicenter propensity-matched cohort study.

Long-term survival comparison of first-line pembrolizumab versus pembrolizumab plus chemotherapy for patients with advanced non-small cell lung cancer: A multicenter propensity-matched cohort study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: August 12, 2025

Timing of first pembrolizumab infusion and long-term outcomes in non-small cell lung cancer: A retrospective multicenter study.

Timing of first pembrolizumab infusion and long-term outcomes in non-small cell lung cancer: A retrospective multicenter study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 19, 2025

Showing 1-12 of 119

Last Updated: 09/26/2026